DEAN J MITCHELL
CIK 1199297 · President and CEO · last filed 2026-06-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$9.93M
Companies
10
Total Filings
111
Lifetime Open-Market Net
$591.5K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TBPH | Director | 97,213 | $16.89 | $1.64M | $0 | 12 | 2026-06-16 |
| PRAX | Director | 18,622 | $295.81 | $5.51M | $87.0K | 9 | 2026-06-12 |
| PGEN | Director | 503,183 | $5.53 | $2.78M | $35.2K | 13 | 2024-03-18 |
| ImmunoGen, Inc. (IMGN) Delisted | Director | 0 | $31.23 | $0 | $125.1K | 42 | 2024-02-12 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | — | $2.65 | — | $0 | 3 | 2023-06-13 |
| PRECIGEN, INC. (XON) Delisted | Director | 49,661 | — | — | $91.6K | 12 | 2019-03-26 |
| ISTA PHARMACEUTICALS INC (ISTA) Delisted | Director | 4,932 | — | — | $0 | 5 | 2011-12-07 |
| Talecris Biotherapeutics Holdings Corp. (TLCR) Delisted | Director | 3,019 | — | — | $0 | 2 | 2010-04-05 |
| ALPHARMA INC (ALO) Delisted | President and CEO | 80 | — | — | $252.5K | 8 | 2008-12-31 |
| MGI PHARMA INC (MOGN) Delisted | Director | 3,887 | — | — | $0 | 1 | 2007-05-09 |
Recent Filings · Page 2 of 12
111 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-02-12 | ImmunoGen, Inc. (IMGN) Delisted | Disp (D) | −103,000 | $0 | EDGAR |
| 2023-12-19 | ImmunoGen, Inc. (IMGN) Delisted | Exer (M) | +10,000 | $147.0K | EDGAR |
| 2023-09-26 | ImmunoGen, Inc. (IMGN) Delisted | Exer (M) | +10,000 | $147.0K | EDGAR |
| 2023-09-25 | PGEN | Buy (P) | +25,000 | $35.2K | EDGAR |
| 2023-06-16 | ImmunoGen, Inc. (IMGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-14 | PRAX | Grant (A) | — | $0 | EDGAR |
| 2023-06-13 | Kinnate Biopharma Inc. (KNTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-04 | TBPH | Grant (A) | +9,132 | $0 | EDGAR |
| 2023-03-27 | PRAX | Buy (P) | +50,000 | $41.8K | EDGAR |
| 2023-03-13 | PGEN | Grant (A) | +48,290 | $56.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.